Aptar Acquires Nanopharm and Gateway Analytical, Broadening Pharma Services Platform to Accelerate Customer Drug Development

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. today announced that it has acquired two leading
pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical
LLC, for a combined enterprise value of approximately $50 million. The
acquisitions are part of Aptar’s strategy to broaden its portfolio of
services that support pharmaceutical and biotech customers to accelerate
and derisk their complex product developments.

Both acquisitions bring complementary, value-added and differentiated
analytical, testing and development services for all stages of drug
development and commercialization. The expanded services platform will
enable Aptar Pharma to collaborate earlier with customers to support
their complex drug formulations and delivery requirements as they face
increasingly competitive and regulated markets.

Nanopharm, located in Newport, UK, is a science-driven, leading provider
of orally inhaled and nasal drug product design and development
services. Gateway Analytical, located in Gibsonia, PA, provides
industry-leading particulate detection and predictive analytical
services to customers developing injectable medicines. The companies’
results will be included in the Pharma segment and the transactions are
not expected to be dilutive to Aptar’s earnings in 2019.

“We are delighted to welcome the talented teams of Nanopharm and Gateway
and their customers to Aptar Pharma,” commented Gael Touya, President of
Aptar Pharma. “Their expertise and capabilities will deepen our current
range of services offered to customers who are developing and testing
inhaled and injected medicines. This enables us to participate in a
broader spectrum of the pre-clinical, clinical trial and market launch
phases of drug development.”

Stephan Tanda, President and CEO, stated, “These strategic investments
further strengthen our best in class Pharma business and increase our
ability to add to our long-term growth pipeline by adding depth to our
service offerings. The expertise of two established leaders, Nanopharm,
a leader in inhalation and nasal drug development services, and Gateway,
a leader in particulate detection and analysis for the injectables
market, are complementary to our existing laboratory and analytical
services and will bring additional value to our customers as they
navigate the challenging regulatory landscape and seek to bring their
products to market faster.”

About Aptar

Aptar is a leading global supplier of a broad range of innovative
dispensing, sealing and active packaging solutions for the beauty,
personal care, home care, prescription drug, consumer health care,
injectables, food and beverage markets. Aptar uses insights, design,
engineering and science to create innovative packaging technologies that
build brand value for its customers, and, in turn, make a meaningful
difference in the lives, looks, health and homes of people around the
world. Aptar is headquartered in Crystal Lake, Illinois and has over
14,000 dedicated employees in 18 different countries. For more
information, visit www.aptar.com.

About Nanopharm

Nanopharm is a leading provider of tailored analytical and drug
development services, with a focus on orally inhaled and nasal drug
products. The company’s unique processing technologies and formulation
development tools enable seamless translation of pre-clinical
development through to clinical manufacturing. Nanopharm’s integrated
development services in materials characterization, formulation
development and inhaled biopharmaceutics aids successful product
development by understanding how material properties and processing
conditions influence product functionality. For more information, visit www.nanopharm.co.uk.

About Gateway Analytical

Gateway Analytical is the innovative analytical testing laboratory that
businesses around the world trust to provide solutions for their most
challenging foreign particulate analysis, foreign particulate
identification and materials analysis needs. Gateway’s expert
scientists, specialized testing techniques and comprehensive analysis
methods allow the company to deliver the fast, accurate and reliable
results that customers in the pharmaceutical, materials and medical
device industries demand. To learn more about Gateway Analytical and how
it is making the world healthier and safer, visit www.gatewayanalytical.com.

This press release contains forward-looking statements. Words such as
“future” and other similar expressions or future or conditional verbs
such as “will” are intended to identify such forward-looking statements.
Forward-looking statements are made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 and are based on our beliefs as
well as assumptions made by and information currently available to us.
Accordingly, our actual results may differ materially from those
expressed or implied in such forward-looking statements due to known or
unknown risks and uncertainties that exist in our operations and
business environment including, but not limited to: the successful
integration of acquisitions; significant fluctuations in foreign
currency exchange rates; and competition, including technological
advances. For additional information on these and other risks and
uncertainties, please see our filings with the Securities and Exchange
Commission, including the discussion under “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results
of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no
obligation to update any forward-looking statements, whether as a result
of new information, future events or otherwise.

Contacts

Investor Relations Contact:
Matt DellaMaria
AptarGroup,
Inc.
+1 815 477 0424
[email protected]

Media Contact:
Aptar Pharma
Carolyn Penot
+33 1 39
17 20 38
[email protected]